Literature DB >> 9894142

Quality of life. Issues for persons with neuromuscular diseases.

R T Abresch1, N K Seyden, M A Wineinger.   

Abstract

Improving quality of life has always been a goal of rehabilitation medicine. However, health care providers often do not know much about the quality of life of individuals with neuromuscular diseases, nor what factors are critical to achieving a good quality of life. Lack of knowledge about subjective quality of life factors can negatively influence expectations and selection of treatments. In the most glaring cases, a physician's subjective but incorrect assessment of a disabled individuals' quality of life may prevent life-sustaining interventions. As a group, the quality of life of individuals with NMD is not much different than nondisabled controls and is substantially better than presumed by the general public and, often times, by health care workers. Nevertheless, their quality of life is reduced in certain areas. Surprisingly, level of disability is not a critical factor that significantly alters life satisfaction. Presumably, this is because physical functioning has been adequately managed. The greatest problems that individuals with neuromuscular disease identified were: lack of information about the disease and services; poor coordination of services; negative attitudes; and a diminished expectation of their potential. In addition, people with severe disabilities had significant problems obtaining, financing, and managing personal care attendants. Factors related to a good quality of life were related to perceived control, perceived health status, but not disability. The more that people could do for themselves, either on their own or with personal care assistants, assistive devices, and use of technology, the better their quality of life.

Entities:  

Mesh:

Year:  1998        PMID: 9894142

Source DB:  PubMed          Journal:  Phys Med Rehabil Clin N Am        ISSN: 1047-9651            Impact factor:   1.784


  8 in total

Review 1.  What has the mdx mouse model of Duchenne muscular dystrophy contributed to our understanding of this disease?

Authors:  Jennifer Manning; Dervla O'Malley
Journal:  J Muscle Res Cell Motil       Date:  2015-02-11       Impact factor: 2.698

2.  Mobility difficulties are not only a problem of old age.

Authors:  L I Iezzoni; E P McCarthy; R B Davis; H Siebens
Journal:  J Gen Intern Med       Date:  2001-04       Impact factor: 5.128

Review 3.  The role of the neuromuscular medicine and physiatry specialists in the multidisciplinary management of neuromuscular disease.

Authors:  Craig M McDonald; William M Fowler
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-08       Impact factor: 1.784

4.  If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD).

Authors:  James E Hilbert; John T Kissel; Elizabeth A Luebbe; William B Martens; Michael P McDermott; Donald B Sanders; Rabi Tawil; Charles A Thornton; Richard T Moxley
Journal:  Contemp Clin Trials       Date:  2011-11-26       Impact factor: 2.226

Review 5.  A systematic review of quality of life in adults with muscle disease.

Authors:  Christopher D Graham; Michael R Rose; Elizabeth A Grunfeld; Simon D Kyle; John Weinman
Journal:  J Neurol       Date:  2011-05-20       Impact factor: 4.849

Review 6.  Therapeutic misconception: hope, trust and misconception in paediatric research.

Authors:  Simon Woods; Lynn E Hagger; Pauline McCormack
Journal:  Health Care Anal       Date:  2014-03

7.  Participation and quality of life in children with Duchenne muscular dystrophy using the International Classification of Functioning, Disability, and Health.

Authors:  Roxanna M Bendixen; Claudia Senesac; Donovan J Lott; Krista Vandenborne
Journal:  Health Qual Life Outcomes       Date:  2012-05-22       Impact factor: 3.186

8.  Living with muscular dystrophy: health related quality of life consequences for children and adults.

Authors:  Martha A Grootenhuis; Judith de Boone; Anneke J van der Kooi
Journal:  Health Qual Life Outcomes       Date:  2007-06-06       Impact factor: 3.186

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.